Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David DL Bowtell; Ronny Drapkin

Journal article

Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

Alison M Karst, Paul M Jones, Natalie Vena, Azra H Ligon, Joyce F Liu, Michelle S Hirsch, Dariush Etemadmoghadam, David DL Bowtell, Ronny Drapkin

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2014

DOI: 10.1158/0008-5472.CAN-13-2247

University of Melbourne Researchers

David Bowtell Author The Sir Peter MacCallum Department of Oncology

Dariush Etemadmoghadam Author Clinical Pathology

Related Projects (1)

Cyclin E1 as a therapeutic target in women with high-grade serous cancer and primary treatment failure

Ovarian cancer is the 5th most common cancer in women and the most lethal gynaecologic malignancy. We found tumours with extra copies of the..

Grants

Awarded by National Cancer Institute

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This work was supported by grants from the National Cancer Institute at the NIH P50-CA105009 (R. Drapkin), NIH U01 CA-152990 (R. Drapkin), NIH R21 CA-156021 (R. Drapkin); the Honorable Tina Brozman 'Tina's Wish' Foundation (R. Drapkin), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (R. Drapkin), the Robert and Debra First Fund (R. Drapkin), the Gamel Family Fund (R. Drapkin), a Canadian Institutes of Health Research Fellowship (A. M. Karst), a Kaleidoscope of Hope Foundation Young Investigator Research Grant (A. M. Karst), and a National Health and Medical Research Council project grant (APP 1042358; D. D. L. Bowtell).